recurrence-free survival

Neoadjuvant Intralesional Daromun Significantly Improves Outcomes in Resectable Stage III Melanoma: Insights from the PIVOTAL Phase III Trial Update

By MedXY 08/13/2026

Updated PIVOTAL Phase III trial data demonstrate that neoadjuvant intralesional Daromun significantly improves recurrence-free and distant metastasis-free survival in resectable stage III melanoma without new safety concerns at 36.8 months median follow-up.

news Oncology Radiology

Advancing Precision Prognosis in High-Grade Serous Ovarian Cancer via Multi-Time Point Radiomics and Clinical Data Integration

By MedXY 07/05/2026

This study demonstrates that combining clinical variables with computed tomography radiomics features improves the prediction of recurrence-free survival in high-grade serous ovarian cancer patients undergoing neoadjuvant chemotherapy and surgery.

Dermatology Oncology

Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety

By MedXY 10/25/2025

The 9-year follow-up of the CheckMate 238 trial confirms that nivolumab offers longer recurrence-free survival than ipilimumab in resected stage III/IV melanoma, with durable safety and favorable distant metastasis-free survival.